Invitrogen Presents Depth of Innovations at BIO 2006 Conference
Friday April 7, 12:00 pm ET
CARLSBAD, Calif.--(BUSINESS WIRE)--April 7, 2006--Invitrogen Corporation (Nasdaq:IVGN - News), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, will be engaging partners, customers and industry peers in thought-provoking dialogue about major trends and opportunities at the Biotechnology Industry Organization's BIO 2006 Chicago Annual International Conference taking place Sunday, April 9 through Wednesday, April 12 at McCormick Place.
ADVERTISEMENT
Regenerative Medicine Track Sponsor
As a co-sponsor of the Regenerative Medicine track of Breakout Sessions, Invitrogen is demonstrating its commitment to helping scientists tackle the unique challenges of working in the rapidly advancing arena of stem cells. The company has one of the largest stem cell research teams in the industry and is the world's leading provider of stem cell products and services that enable researchers worldwide to continually expand the boundaries of regenerative medicine. Leaders from Invitrogen's stem cell team will be addressing emerging opportunities in embryonic stem cell medicine and new developments in California's stem cell funding landscape during panel discussions at the Breakout Sessions.
Expert Panelists on Nanotechnology, Molecular Diagnostics, and Drug Discovery
Representatives from Invitrogen will also be speaking at several additional Breakout Sessions, addressing trends related to myriad opportunities in molecular diagnostics and nanobiotechnology, as well as practicable, successful models for accelerating the drug development process.
"Every year, BIO gives us an opportunity to communicate with a broad audience about the positive impact Invitrogen has on our industry and our community," said Gregory T. Lucier, chairman and CEO of Invitrogen. "This year, especially, we have an exciting opportunity to highlight programs - nanotechnology, diagnostics and regenerative medicine among them - that involve some of our most advanced technologies and are less familiar to many of our audiences."
Corporate Citizenship
Under the auspices of Invitrogen's corporate citizenship program, senior vice president Peter Leddy, Ph.D. will co-present the Biotechnology Institute's Genzyme-Invitrogen Biotech Educator Award at the organization's "Education: The Foundation of Innovation" reception and dinner. The honorees include seven high-school educators, representing a premier group of teachers who bring biotechnology to their classrooms and provide an array of expertise to help improve the teaching and learning of biotechnology. Invitrogen is a multi-year sponsor of the year-round effort to train teachers nationwide.
Celebrating Science
Invitrogen is also sponsor of the Chemical Heritage Foundation and BIO's 8th Annual Biotechnology Heritage Award, which will be given to industry pioneer Alejandro Zaffaroni, founder of several biotechnology companies and someone who truly exemplifies innovation. The presentation will be made at the Monday, April 10 plenary breakfast.
To learn more about Invitrogen's corporate citizenship initiative, as well as the nearly 25,000 products and services that the company provides, Invitrogen invites conference attendees to "Take a Look Inside" at its booth #741 in the Exhibit Hall A1, South Building. On Tuesday, April 11 from 5:00pm to 6:30pm, the company will serve San Diego's famous fish tacos and regional fare during its hospitality event.
For more information about BIO 2006, visit bio.org.
Invitrogen Participating in Panel Discussions at Breakout Sessions:
Emerging Opportunities in Embryonic Stem Cell Medicine
Track: Regenerative Medicine
Monday, April 10, 2006, 9:15 - 10:45 AM
Invitrogen Panelist: Mahendra Rao, Vice President, Research, Stem
Cells and Regenerative Medicine, Invitrogen Corporation
Companion Diagnostics: It's Not Just About a Better Drug
Track: Devices and Diagnostics
Monday, April 10, 2006, 9:15 - 10:45 AM
Invitrogen Panelist: William Sweet, Director of Clinical and
Research Affairs
Venturing Into Diagnostics: Realizing the Value of the New Diagnostics
Track: Devices and Diagnostics
Monday, April 10, 2006, 11:00 AM - 12:30 PM
Invitrogen Panelist: Todd Nelson, Vice President, Corporate
Development
Public-Private Partnerships for Translational Medicine
Track: Business Development
Tuesday, April 11, 2006, 11:00 AM - 12:30 PM
Invitrogen Panelist: Benjamin Bulkley, Senior Vice President, Global
Commercial Operations
Systems Biology - Where Do We Stand? Evaluating the Current and Future
Impact on Therapeutic and Diagnostic Research Development
Track: Hot Topics
Tuesday, April 11, 11:00 AM - 12:30 PM
Invitrogen Panelist: Joseph Beechem, CSO, Invitrogen Corporation
New Developments in California's Stem Cell Gold Rush
Track: Regenerative Medicine
Tuesday, April 11, 2006, 2:00 - 3:30 PM
Invitrogen Panelist: Joydeep Goswami, Vice President, Stem Cells and
Regenerative Medicine
Making a Science out of Research and Development
Track: Drug Discovery and Development
Wednesday, April 12, 2006, 4:00 - 5:30 PM
Invitrogen Panelist: Rob Bennett, Vice President, Life Sciences R&D
About Invitrogen
Invitrogen Corporation (Nasdaq:IVGN - News) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 scientists and other professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com. |
